Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7673396 in Advanced Solid Tumors With RAS Mutations
NCT06884618Phase 1Recruiting
- Sponsor
- Roche
- Start
- Apr 2025
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 1, open-label trial of RG6505 in solid tumor (2 arms), sponsored by Roche. Primary endpoints: Adverse Events at 40 months, Dose-limiting Toxicities at 21 days and 1 more. Started Apr 2025; status: recruiting.
02
Drugs
RG6505
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06884618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06884618.